Trade Report: The Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Receives $54.89 Consensus Target Price from Brokerages

The Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Receives $54.89 Consensus Target Price from Brokerages

Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) have been assigned a consensus rating of “Buy” from the ten analysts that are covering the stock. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $54.89.

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $50.00 target price on shares of Aerie Pharmaceuticals in a research note on Saturday. Stifel Nicolaus boosted their target price on shares of Aerie Pharmaceuticals from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday. Brean Capital reaffirmed a “buy” rating and issued a $63.00 price objective (up from $48.00) on shares of Aerie Pharmaceuticals in a research note on Thursday. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th. Finally, HC Wainwright began coverage on shares of Aerie Pharmaceuticals in a research note on Tuesday, September 20th. They issued a “buy” rating and a $66.00 price objective for the company.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 40.49 on Thursday. The stock’s 50 day moving average is $28.57 and its 200-day moving average is $19.49. The stock’s market cap is $1.13 billion. Aerie Pharmaceuticals has a one year low of $10.82 and a one year high of $41.72.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.02. On average, equities analysts forecast that Aerie Pharmaceuticals will post ($2.81) EPS for the current year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of Aerie Pharmaceuticals stock in a transaction on Friday, July 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 8.77% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the company. First Mercantile Trust Co. purchased a new position in shares of Aerie Pharmaceuticals during the third quarter worth approximately $161,000. Schwab Charles Investment Management Inc. increased its position in shares of Aerie Pharmaceuticals by 25.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,544 shares of the company’s stock worth $661,000 after buying an additional 7,700 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Aerie Pharmaceuticals by 16.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,893 shares of the company’s stock worth $315,000 after buying an additional 2,544 shares in the last quarter. Iguana Healthcare Management LLC increased its position in shares of Aerie Pharmaceuticals by 100.0% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the company’s stock worth $2,640,000 after buying an additional 75,000 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $36,960,000 after buying an additional 75,000 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.

Related posts

Leave a Comment